Major Benefit From Antiplatelet Therapy for Patients at High Risk for Adverse Cardiac Events After Coronary Palmaz-Schatz Stent Placement
- 15 April 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 95 (8) , 2015-2021
- https://doi.org/10.1161/01.cir.95.8.2015
Abstract
Background The Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial is a randomized study in which antiplatelet therapy is compared with anticoagulant therapy after coronary stent placement, showing a significantly lower rate of noncardiac and cardiac events with antiplatelet therapy. The present study is a report of the analysis of a prospective risk stratification protocol in the ISAR Trial and the association with the incidence of adverse cardiac events and stent vessel occlusion. Methods and Results In all 517 patients randomized in the ISAR Trial, risk stratification was done with a list of 18 clinical, procedural, and angiographic variables: 165 patients with two or fewer criteria were classified as low risk, 148 patients with three criteria were classified as intermediate risk, and 204 patients with four or more criteria were classified as high risk. Within a 30-day follow-up, cardiac event rate (death, myocardial infarction, repeat intervention) was 6.4% for high-risk, 3.4% for intermediate-risk, and 0% for low-risk patients ( P <.01). Stent vessel occlusion occurred in 5.9%, 2.7%, and 0%, respectively ( P <.01). There was no significant difference between anticoagulant and antiplatelet therapy in the low- and intermediate-risk groups. In high-risk patients, however, the cardiac event rate was 12.6% with anticoagulant therapy and 2.0% with antiplatelet therapy ( P =.007), and the rate of stent vessel occlusion was 11.5% and 0%, respectively ( P <.001). Conclusions This risk stratification protocol can help to identify patients at risk for adverse cardiac events and stent vessel occlusion. Patients in the high-risk group had the most benefit from antiplatelet therapy. These data suggest that antiplatelet therapy is the therapy of choice after coronary stenting specifically for patients with acute ischemic syndromes, difficult procedures, or suboptimal final results.Keywords
This publication has 11 references indexed in Scilit:
- A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery StentsNew England Journal of Medicine, 1996
- Stratification of the risk of thrombosis after intracoronary stenting for threatened or acute closure complicating coronary balloon angioplasty: A Cook registry studyAmerican Heart Journal, 1995
- Caveats about Elective Coronary StentingNew England Journal of Medicine, 1994
- A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 1994
- A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery DiseaseNew England Journal of Medicine, 1994
- Thrombosis and restenosis after stenting in failed angioplasty: Comparison with elective stentingAmerican Heart Journal, 1994
- Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: Clinical and angiographic outcomesJournal of the American College of Cardiology, 1993
- Thrombosis of a flexible coil coronary stent: Frequency, predictors and clinical outcomeJournal of the American College of Cardiology, 1993
- Best Subsets Logistic RegressionBiometrics, 1989
- Intravascular Stents to Prevent Occlusion and Re-Stenosis after Transluminal AngioplastyNew England Journal of Medicine, 1987